Central Registry

(1) All OBOT Plus facilities shall participate in the Central Registry. (2) Patients shall be informed of the Facility’s participation in the Central Registry. Prior to initiating a central registry inquiry, the Facility shall obtain the service recipient’s written consent. (3) To prevent simultaneous enrollment of a service recipient in more than one OBOT Plus, the Facility shall initiate a clearance inquiry by submitting to the Central Registry the name, date of birth, or any other relevant information required for the clearance procedure or as required by the SOTA prior to dispensing buprenorphine products. No person who is reported by the Central Registry to be enrolled at another such Facility shall be admitted to an OBOT Plus, or in the event a multiple enrollment is found, the patient shall not continue to be dispensed buprenorphine until the patient enrollment status is active solely at a single OBOT Plus where the patient is currently receiving buprenorphine products. (4) Reports received by the Central Registry shall be treated as confidential and shall not be released except to a licensed OBOT Plus facility, or its designated legal representative, or as approved by the SOTA, or as required by law. Information made available by the Central Registry to Facilities or their designated legal representatives or as approved by the SOTA shall also be treated as confidential.